This theme aims to:

– Improve the quality, reliability, and accessibility of the evidence that underpins medications, devices, operations, and other therapeutic interventions

– Expose and challenging healthcare claims and regulatory failings that prioritise commercial interests over the interests of the public

– Improve understanding, transparency, and reporting of harms from medicines and other therapeutic interventions

Examples of our research in this area are shown below

The Primodos Story

Oral hormone pregnancy tests such as Primodos, containing ethinylestradiol and very high doses of norethisterone, were given to over a

Read More

Salt intake in heart failure patients

Researchers: Mahtani KR, Heneghan CJ, Nunan D, Onakpoya IJ, Roberts NW, Hobbs FDR

Read More

New treatments for atrial fibrillation

This is a pre-publication version of an editorial appearing in the BMJ by Kamal R. Mahtani and Carl Heneghan We

Read More

Neuraminidase Inhibitors

Tom Jefferson – “The neuraminidase inhibitors evidence of harms – in context” This is an Accepted Manuscript of an article

Read More

High costs of orphan medicines

Do the high costs of orphan medicines (medicines used to treat rare diseases) provide good value for money? This is

Read More

Time-dependent bias in oseltamivir

Time-dependent bias is not an issue in randomised studies as treatment (including placebo) is given at the beginning of follow

Read More

Tamiflu Re-analysis

On 30.1.15 the Lancet published a re-analysis of Oseltamavir effects in symptomatic influenza like illness “Oseltamivir treatment for influenza in

Read More


If you wanted to conduct an independent assessment of the clinical usefulness of a drug, would it be wise to

Read More

Oseltamivir results, harms and peer review

I have concerns with the undertaking of the Dobson paper [1] in the Lancet: how the results are presented, the

Read More

Oseltamivir for preventing influenza

Summary of Oseltamivir versus placebo for preventing influenza in adults * Oseltamivir for influenza in adults and children: systematic review

Read More

Scepticism advice on anti flu drugs

This is our response posted on the BMJ to @deb_cohen  article on ‘GPs are told to treat with scepticism advice

Read More

Zanamivir for influenza in adults and children

Abstract Objectives To describe the potential benefits and harms of zanamivir. Design Systematic review of clinical study reports of randomised

Read More

Oseltamivir for influenza in adults and children

Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments Abstract Objective

Read More

Weight loss supplements: do they work?

An offshoot of the increased prevalence of overweight and obesity is the proliferation in the market of weight loss supplements

Read More

16th edition due to be published in 2015: "Meyler's Side Effects of Drugs

Jeff Aronson has edited the forthcoming 16th edition of “Meylers Side Effects of Drugs: the International Encyclopedia of Adverse Drug Reactions and

Read More